GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cadrenal Therapeutics Inc (NAS:CVKD) » Definitions » FCF Margin %

CVKD (Cadrenal Therapeutics) FCF Margin % : 0.00% (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Cadrenal Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Cadrenal Therapeutics's Free Cash Flow for the three months ended in Dec. 2024 was $-1.79 Mil. Cadrenal Therapeutics's Revenue for the three months ended in Dec. 2024 was $0.00 Mil. Therefore, Cadrenal Therapeutics's FCF Margin % for the quarter that ended in Dec. 2024 was 0.00%.

As of today, Cadrenal Therapeutics's current FCF Yield % is -24.20%.

The historical rank and industry rank for Cadrenal Therapeutics's FCF Margin % or its related term are showing as below:


CVKD's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -129.705
* Ranked among companies with meaningful FCF Margin % only.

Cadrenal Therapeutics FCF Margin % Historical Data

The historical data trend for Cadrenal Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cadrenal Therapeutics FCF Margin % Chart

Cadrenal Therapeutics Annual Data
Trend Dec22 Dec23 Dec24
FCF Margin %
- - -

Cadrenal Therapeutics Quarterly Data
Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cadrenal Therapeutics's FCF Margin %

For the Biotechnology subindustry, Cadrenal Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cadrenal Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cadrenal Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Cadrenal Therapeutics's FCF Margin % falls into.


;
;

Cadrenal Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Cadrenal Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-7.365/0
= %

Cadrenal Therapeutics's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=-1.791/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cadrenal Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Cadrenal Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cadrenal Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cadrenal Therapeutics Inc (NAS:CVKD) » Definitions » FCF Margin %
Comparable Companies
FBLG ALXO KPTI NRXP OSTX LVTX RNXT TPST AKTX SRZN VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
822 A1A North, Suite 306, Ponte Vedra, FL, USA, 32082
Website
https://www.cadrenal.com
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
Executives
John Raymond Murphy director 233 S PATTERSON AVE, SPRINGFIELD MO 65802
Quang X Pham director, 10 percent owner, officer: CEO and Chairman 89 MELROSE DRIVE, MISSION VIEJO CA 92692
Robert Lisicki director C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Douglas W Losordo officer: Chief Medical Officer 13 FOX MEADOW RD, SCARSDALE NY 10583
Steven Zelenkofske director 120 MOUNTAIN VIEW BOULEVARD, BASKING RIDGE NJ 07920
Matthew K Szot officer: Chief Financial Officer 802 NORTH DOUTY STREET, HANFORD CA 93230
Glynn Wilson director 2483 NE JULEP STREET, ISSAQUAH WA 98029